Laboratory-related transfusion errors - information technology is not a foolproof solution : 1
Rapid, comprehensive diagnosis for unexplained anaemia : 2
Antenatal screening programme in a low prevalence area: Is it effective? : 3
National comparative audit of red cell transfusion in medical patients - part two : 4
Red cell transfusions: delays in setting up and extended transfusion times have not been associated with any adverse outcomes - analysis of 30 months' data reported to SHOT : 5
Adverse events related to blood transfusion: haemoglobinopathy patients are particularly at risk : 6
Subcortical volumetric differences in children with sickle cell disease : 7
Eculizumab in paroxysmal nocturnal haemoglobinuria (PNH): a report of all 153 patients treated in the UK : 8
Characterisation of a dynamic in vitro circulation system designed to model the interaction between primary CLL cells and endothelial cells in the peripheral vasculature : 9
The addition of bortezomib to standard dose CHOP chemotherapy significantly improves survival in relapsed mantle cell lymphoma - final analysis of a randomised UK NCRN trial : 10
Pro-thrombotic properties of circulating histones cause microcirculatory obstruction and acute respiratory failure : 11
The effect of Duffy antigen receptor for chemokines (DARC) on severity in sickle cell disease : 12
Inhibition of the chemokine receptor CXCR4 favours central nervous system engraftment in a xenograft model of childhood pre-B acute lymphoblastic leukaemia : 13
A phase II study (PX-171–003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM) : 14
Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: Stage 1 results of the phase III SABRINA study (BO22334) : 15
Superior response durability following a second autologous stem cell transplant (ASCT) for relapsed multiple myeloma (MM): results from the BSBMT/UKMF myeloma × (Intensive) trial : 16
Monitoring circulating histone levels as an indication clinically of activated coagulation and endothelial damage : 17
Characteristics and outcome of children and young adults with Early T-Precursor (ETP) ALL treated on UKALL 2003 : 18
Outcome of allogeneic haematopoietic stem cell transplant for philadelphia chromosome positive acute lymphoblastic leukaemia in paediatric patients in the era of tyrosine kinase inhibitors and strategies for management of relapse: a UK multicentre study : 19
Early lymphocyte recovery is associated with superior survival but does not refine minimal residual disease based risk stratification in children with precursor B acute lymphoblastic leukemia : 20
Hypocupremia associated cytopenia and myelopathy: a national retrospective review : 21
The use of mycophenolate mofetil in the treatment of chronic refractory immune thrombocytopenia purpura : 22
Atypical congenital dyserythropoietic anaemia: a novel mutation in LPIN2 causes Majeed syndrome with incomplete penetrance : 23
Can the paediatric bleeding questionnaire be used to guide investigation of children referred to a tertiary haemostasis clinic? : 24
Characterisation of Ikaros (IKZF1) deletions in paediatric patients with acute lymphoblastic leukaemia (ALL) using multiplex ligation-dependent probe amplification (MLPA) : 163
Genetics of teenage and young adult t-cell acute lymphoblastic leukaemia : 168
Pulmonary embolism in the community - are we missing opportunities for preventing deaths? : 25
Discrepant one-stage clotting versus chromogenic FVIII assays in haemophilia patients on Refacto AF : 26
The Bethesda assay in isolation significantly underestimates the presence of factor VIII antibodies in acquired haemophilia A : 27
Role of complement in acute TTP : 28
Tissue factor-dependent pathway in severe preeclampsia revisited: a Brazilian cohort study : 29
Benefit of early administration of rituximab in acute TTP and prophylactic use to prevent relapse : 30
A local service evaluation to demonstrate the impact of a multi-faceted intervention for the management of severe haemophilia at Leicester Haemophilia Comprehensive Care Centre (LHCCC) : 31
Outcome of liver transplantation in patients with hereditary bleeding disorders: a single centre UK experience : 32
Sequestration of cellular ABL signal protein is associated with the ineffective maturation and cytoskeletal function of dendritic cells from chronic myeloid leukaemia : 33
‘Druggable’ autophagy genes are suppressed in CML stem/progenitor cells compared to their normal counterparts and up-regulated following Bcr-Abl inhibition : 34
Degradation characteristics of the major PML isoforms in response to arsenic : 35
Cytoreductive treatment patterns for essential thrombocythaemia in Europe: analysis of 3643 patients in the EXELS study : 36
Autoimmune haemolytic anaemia after allogeneic haematopoietic stem cell transplantation: analysis of 555 transplant patients at King's College Hospital : 37
Peptide vaccination using combined adjuvants for synergistic activation of cellular immunity (CASAC) promotes potent WT1-specific immune responses in an in vivo mouse model : 38
Pharmacogenetic analysis of CYP2B6 in the LRF CLL4 trial: the *6 allelic variant is associated with inferior efficacy following fludarabine plus cyclophosphamide : 39
Lck is an important mediator of BCR-induced signalling in chronic lymphocytic leukaemia cells : 40
Chemokine unresponsiveness of chronic lymphocytic leukaemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy : 41
Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials : 42
Classifying amyloidosis by mass spectrometrybased proteomics in routine clinical practice: Mayo Clinic experience : 43
Treatment outcomes of 299 elderly (≥75 years) patients with systemic AL amyloidosis : 44
Audit of data quality in multidisciplinary meetings database : 45
Bone marrow necrosis and systemic fat embolism in sickle cell disease: the ‘protective’ role of the SS genotype and a possible association with parvovirus B19 infection : 46
Annual British Society for Haematology confidential survey of bone marrow examination associated adverse events 2011 : 47
A retrospective audit of coagulation screen testing on elective surgical patients : 48
Serum β2 microglobulin levels in human immune deficiency virus (HIV) infected patients in South-South Nigeria : 49
Subcutaneous bortezimib: the Moreau Study versus Newport and Cardiff Hospital - has the Moreau Study influenced the type of patients being prescribed Bortezimib? : 50
The signs, symptoms and health-seeking behaviours of neutropenic sepsis patients before they reach hospital: a qualitative study : 51
Neutropaenia found on routine laboratory testing - is follow-up required? : 52
CD4+ cell count mean value, reference range and its influencing factors in HIV-seronegative pregnant women in Lagos : 53
Thrombocytopenia and splenomegaly in pregnancy: a common presenting feature of Gaucher disease in females : 54
Improving morphological identification of haematopoietic cells and malaria species using an online gallery produced for the WHO : 55
A prospective audit of haematinic requests from general practice in Cork University Hospital (CUH) Haematology Laboratory : 56
Exploring perceptions of end of life care in haematology : 57
An investigation into parameters that can predict bone marrow engraftment post transplantation using the newly introduced Sysmex XN analyser : 58
Are antifungal protocols worthwhile? Do they affect practice? : 59
Use of the thrombopoietin analogue (Romiplostim®) in the south west peninsula : 60
Entonox, in addition to local anaesthetic, improves pain and patients' experience during bone marrow aspirate and trephines (BMATs) : 61
Platelet count reference range of normal pregnant women in Lagos, Nigeria : 62
Late discovery of a case with TAR syndrome who presented with an additional potential bleeding risk other than thrombocytopenia : 63
Heterogeneity of inherited bone marrow failure syndromes and delay in diagnosis : 64
Implementing new guidelines for the management of iron deficiency anaemia in pregnancy - incorporating the views of health care professionals and user groups : 65
Review of bone marrow examination quality in a university teaching hospital and referring peripheral hospitals : 66
Abstract Withdrawn : 67
Management of venous thromboembolism in cancer patients at a district general hospital : 68
Can patients aged 60–69 years with deep vein thrombosis be safely and effectively anticoagulated with a 9 mg loading dose of warfarin? : 69
D-dimer and biomarkers of fibrin formation in the early diagnosis and prognosis of sepsis : 70
Improving outcomes: development of a vena cava filter insertion and removal service : 71
An audit of post-procedural anti-coagulation practices in patients undergoing ablation therapy for atrial fibrillation in a UK tertiary centre : 72
Comprehensive venous thromboembolism prevention programme incorporating mandatory electronic risk assessment reduces the incidence of hospital-associated thrombosis : 73
DAWN AC benchmarking provides a method of anticoagulant service comparison and improvement : 74
Hypercoagulable states post-pregnancy: tissue factor and tissue factor pathway inhibitor imbalance in women with a history of preeclampsia : 75
Endothelial dysfunction, coagulation activation and inflammation in preeclampsia : 76
Elevated plasma factor VIII and von Willebrand factor in women with type 2 diabetes: Inflammatory reaction, endothelial perturbation or else? : 77
The use of intranasal bevacizumab to treat recurrent epistaxis due to hereditary haemorrhagic telangiectasia : 78
Should pre-operative assessment clinic include a dedicated service for the management of patients treated with oral anticoagulants? : 79
A single centre retrospective observational study assessing the incidence of hospital acquired thrombosis over a 5 years period spanning the introduction of mandatory venous thromboembolism (VTE) risk assessment for adult patients admitted to hospital : 80
Evaluation of an external quality assessment material for D-dimer point of care testing kits : 81
Retrospective review of incidental VTE findings over 12 months in a teaching hospital : 82
The effect of androgen deprivation therapy in prostatic adenocarcinoma on the coagulation pathway and its implication for cardiovascular risk : 83
Variability in measurement of ADAMTS13: a UK NEQAS multicentre exercise for ADAMTS13 assays : 84
Audit of clinical utilisation of laboratory investigation of suspected antiphospholipid syndrome in a single laboratory : 85
Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation : 86
Accuracy of venous thromboembolism risk assessment and the impact on appropriate thromboprophylaxis in a large teaching hospital : 87
Identification of a novel mutation in Glanzmann's thrombasthenia in a patient presenting with an atypical bleeding history : 88
Rivaroxaban versus enoxaparin: short-term outcome of 1223 patients undergoing lower limb arthroplasty enrolled in an enhanced recovery programme : 89
Warfarin in the over 80s: a risk:benefit assessment : 90
Reduction in the numbers of cancelled operations by the establishment of a cost effective pre-operative bridging clinic : 91
The physchological consequences of experiencing a catastrophic pulmonary embolus: a qualitative study with implications for future intervention : 92
Two case studies showing the importance of Coumarin tracing blood assays to investigate acquired coagulopathies in patients with selfharm behaviour : 93
The value of thrombin generation analysis in thrombotic antiphospholipid syndrome patients on warfarin : 94
Sequential testing - a new consideration when diagnosing HIT : 95
Thrombopoietin receptor agonists for platelet disorders: a retrospective analysis : 96
The United Kingdom immune thrombocytopenic purpura registry : 97
Molecular surveillance for BRAF-V600E mutation in peripheral blood is superior to flow cytometry in hairy cell leukaemia : 98
Three latent proteins of Epstein-Barr virus (EBV) cooperate to suppress transforming growth factor-β (TGFβ) signalling via epigenetic repression of TGFβR2 in B-cells: a possible mechanism for development of EBV-associated B-cell lymphomas : 99
Therapeutic role of dopamine receptors expressed on chronic lymphocytic leukaemia (CLL) cells : 100
Generation of PKCbII transgenic mice for the study of chronic lymphocytic leukaemia : 101
Expression of monocarboxylate transporters -1 and -4 in circulating and CD40L-stimulated chronic lymphocytic leukaemia (CLL) cells : 102
Protein kinase C bII expression is regulated by Sp1 in chronic lymphocytic leukaemia cells : 103
Regulation of integrin α4 expression in CLL cells : 104
Application of high-throughput phosphoproteomic profiling to evaluate tyrosine kinase inhibitor effect in CLL: phosphoprotein profiles correlate with functional behaviour : 105
High expression of TP53 mRNA is associated with allelic loss of 13q14 and short survival in chronic lymphocytic leukaemia : 106
Effects of reducing the DNA replication protein Mcm7 on the chromatin-bound proteome : 107
CCN1 modulates cell growth in aggressive mantle cell lymphoma : 108
Transcriptional insights into the cytoprotection conferred by co-culture of primary chronic lymphocytic leukaemia cells with endothelium : 109
Differential induction of PRDM1 in chronic lymphocytic leukaemia : 110
Physical and functional characterisation of tumour-derived exosomes from chronic lymphocytic leukemia (CLL) patient samples : 111
Assessment of the Bluegnome CytoChip Cancer SNP 4x180K array platform for detection of novel genomic imbalances using a retrospective cohort of eleven diagnostic paediatric acute lymphoblastic leukaemia samples : 112
Increased numbers of circulating cells resembling T follicular helper (Tfh) cells in chronic lymphocytic leukaemia and enhancement of CD154/IL-4 proliferation by the Tfh cytokine, IL-21 : 113
Deficiencies within the classical complement cascade in chronic lymphocytic leukaemia impacts complement dependent cytotoxicity (CDC) following Ofatumumab treatment : 114
Ciclosporine A inhibits T cell activation and has no direct effect on B cell activation in chronic lymphocytic leukaemia : 115
High LCK expression in the malignant cells of chronic lymphocytic leukaemia is a marker of good disease prognosis : 116
A single centre experience of lenalidomide as a third or greater line treatment for relapsed myeloma : 117
Retrospective analysis indicates that CLL and NHL patients have an increased risk of VTE but their detection is often an incidental radiological finding : 118
Richter's transformation of chronic lymphocytic leukaemia (CLL) - better outcomes in the rituximab era? : 119
Outcomes using lenalidomide for secondary relapse of myeloma in East Kent : 120
Non CLL like monoclonal lymphoproliferations in autoimmune diseases : 121
The use of cisplatin and carboplatin in salvage chemotherapy for relapsed lymphoma at a district general hospital : 122
A retrospective, multi-centre analysis of treatment intensification for HIV-positive patients with high-risk diffuse large B-cell lymphoma : 123
BRAF V600E-negative hairy cell leukaemia: an exception to the rule : 124
Management of stage IA diffuse large B cell non-Hodgkin's lymphoma (DLBL): is rituximab really necessary? : 125
Management of diffuse large B cell lymphoma in the ederly: Scottish National Audit 2012 : 126
Subdural haematoma in four lymphoma patients following intrathecal chemotherapy : 127
Laryngo-tracheobronchial amyloidosis - a 30 year institutional experience : 128
Management of Waldenström's macroglobulinaemia: an audit of cases treated at Royal Marsden Hospital, 2000 to 2012 : 129
BSBMT/UKMF Myeloma × Relapse (intensive) Trial - challenges in recruitment and randomisation : 130
Southend University hospital experience of treating lymphomas with thalidomide : 131
Imaging follicular lymphoma at diagnosis using positron emission tomography with 18F-fluorodeoxyglucose; detection of focal transformation within the bone marrow to diffuse large B-cell lymphoma (DLBCL) : 132
Outcomes from a regional nephrology centre for patients with myeloma requiring dialysis as their first presentation : 133
Assessment of IgM, IgA and IgG HevyLite assay for detection of paraproteins in a routine laboratory : 134
Risk adapted treatment of DLBL based on interim PET-CT reduces chemotherapy requirements without compromising excellent outcomes : 135
The value of interim PET-CT in DLBL varies with histological subtype : 136
Self-reported sexual functioning and fertility in long survivors of haematological malignancy: a neglected area of need in the late-effects clinic : 137
Natural killer cells and their clinical correlation in mantle cell lymphoma (MCL) : 138
An audit of compliance with NICE guidelines for use of rituximab as first line maintenance treatment of follicular non-Hodgkin's lymphoma, in line with East Midlands Guidelines : 139
Human immunodeficiency virus related non-Hodgkin's lymphoma undergoing regression on highly active antiretroviral therapy alone (HAART): a case series : 140
Immunohistochemistry of multiple myeloma and impact on overall survival : 141
Effect of ethnicity on presentation characteristics in newly diagnosed myeloma and response to treatment : 142
BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis : 143
Combined targeting of MCL1 with TG02 and BCL2 with ABT-737/ABT-199 as a strategy for eliminating AML cells : 144
The hOCT1 substrate metformin does not alter imatinib, dasatinib or nilotinib uptake into CML cells at clinically relevant concentrations : 145
Histone deacetylase 1 up-regulation may contribute to vorinostat resistance in AML : 146
NPM up-regulates BCL-2 mRNA in NPMc+ AML : 147
Validating the use of combination treatments with the demethylating agent decitabine in acute myeloid leukaemia : 148
Targeting non-cycling acute myeloid leukaemia cells with ABT-737 and ABT-199 : 149
Targeting the HoxA cluster in MLL-fusion leukaemias : 150
Experience with 5-Azacytidine in East Kent: when to quit? : 151
One year of experience with nilotinib: the nurse perspective : 152
JAK2 V617F quantitation versus donor chimerism to monitor engraftment kinetics post-allogeneic haematopoietic stem cell transplantation for myeloproliferative neoplasms : 153
Use of the JAK2 inhibitor ruxolitinib in myelofibrosis relapsing post allogeneic stem cell transplant: case report : 154
Ambulatory care of patients receiving consolidation chemotherapy for acute myeloid leukaemia: a feasible and safe option for selected patients : 155
Chronic myeloid leukaemia in Northern Ireland - a population study 2000 - Present : 156
Radiophosphorus (P32) therapy in myeloproliferative disorders - review of current practice at a university hospital : 157
Defining low and undetectable levels of disease in CML: progress towards standardisation in the UK and Ireland : 158
Improvements in survival for patients with acute myeloid leukaemia over the last three decades - a district general hospital experience : 159
Understanding factors influencing management of myelodysplasia within a cancer network in the UK : 160
Efficacy of pegylated interferon in myelo-proliferative disorders : 161
South Essex use of recombinant human erythropoietin in myelodysplastic syndrome : 162
Combination antiviral and immunoglobulin therapy for adenovirus, cytomegalovirus and parvovirus infections post umbilical cord blood transplant : 164
A paediatric tertiary referral centre experience of OctaplasLG® : 165
The efficacy of IV amphotericin B antifungal prophylaxis in preventing invasive fungal disease (IFD) - a retrospective analysis of patients treated for acute lymphoblastic leukaemia at the Paediatric Haematology and Oncology Department, Addenbrooke's Hospital : 166
An unusual cause of iron deficiency anaemia in two Bulgarian siblings : 167
Causes of severe anaemia (Hb < 5 g/dl) in children (<18 years) between 2006 and 2009 : 169
Vitamin D deficiency in a cohort of children with acute lymphoblastic leukaemia : 170
Audit of indication for neonatal red cell, platelet and fresh frozen plasma (FFP) transfusion against British Committee of Standards for Haematology (BCSH) guidelines at the John Radcliffe Hospital: a need for evidence : 171
Thyrotoxic cardiomyopathy: an initial presentation of alpha-thalassaemia-associated hydrops fetalis : 172
Antibiotic prophylaxis in patients with HbSS disease : 173
Thrombocytopenia associated with automated red cell exchange transfusion in patients with sickle cell disease : 174
Serial serum ferritin measurements for detection of iron overload in transfused patients with sickle cell disease: comparison with liver MRI findings : 175
Hypoadrenalism in sickle cell disease : 176
The significance of unidentified variant haemoglobins found during antenatal haemoglobinopathy screening : 177
Priapism in sickle cell disease: results of a patient questionnaire : 178
Barriers to the optimal use of hydroxycarbamide in sickle cell patients: What can we do different? : 179
Early diagnosis and immediate treatment with eculizumab improves the outcome of Budd-Chiari syndrome (BCS) in paroxysmal nocturnal haemoglobinuria (PNH) : 180
An audit of iron monitoring and outcome - an East London thalassemia population : 181
Longitudinal study of renal function in patients with sickle cell anaemia : 182
Alloimmunisation and sample time to transfusion in thalassaemia : 183
Speed of transfusions in thalassaemia major : 184
Characterisation of haemoglobin (Hb) lepore variants in the UK population : 185
An evaluation of mortality and service engagement in a cohort of adolescents and young adult patients with sickle cell disease (SCD) : 186
Use of high-fidelity simulation for training in management of acute medical emergencies in sickle cell disease : 187
Current management of iron deficiency in pregnancy at a district general hospital : 188
Optimising iron deficiency: the benefits of a nurse-led anaemia service : 189
Peri-operative management of Jehovah's Witnesses undergoing major elective surgery: 10 year experience of the Scottish National Blood Transfusion Service in the Royal Infirmary of Edinburgh : 190
Prevalence of HIV infection among patients attending Delta State University Teaching Hospital, Oghara during the period of January 2011 to April 2011 : 191
My role as a blood transfusion coordinator in a rural new teaching hospital and distribution of ABO and RHD blood groups among patients attending Delta State University Teaching Hospital, Oghara during the period of July 2010 to March 2011 : 192
Donor deferral: a challenge to voluntary blood donation in a developing country : 193
Early use of cryoprecipitate reduces overall blood products requirements in massive transfusions : 194
Dissatisfaction with transfusion training - a snapshot survey of haematology trainees : 195
Retrospective study of the Massive Haemorrhage Protocol adherence in the management of trauma-induced bleeding at the Royal London Hospital : 196
Use of synthetic erythropoietin reduces red cell use & maintains a consistent haemoglobin level : 197
Delays in the transfusion of blood reported to the UK confidential haemovigilance scheme (Serious Hazards of Transfusion) : 198
Adverse incidents related to transfusion - haematology patients are at higher risk for missed specific requirements : 199
The use of plasma-reduced blood components in Scotland: Are we doing it right? : 200
Improved blood conservation following modernisation of Maximum Blood Ordering Schedule (MBOS) : 202
The use of HLA-matched platelets provided by a regional blood transfusion service : 203
Effectiveness of cryoprecipitate use in a cardiothoracic perioperative setting : 204
Distribution of red cell phenotypes in transfused patients with haemoglobinopathies in London - a multicentre audit : 205
Shared post-transplant care: determining the most effective service provision : 206
Cause and frequency of in-patient admissions in the first 6 months post-allogeneic haemopoietic stem cell transplant: Implications for delivery of care : 207